Ali Vasheghani-Farahani

Ali Vasheghani-Farahani


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Asian Journal of Sports Medicine
Verified
Journal Article
Open access
PDF file
AVAli Vasheghani-Farahani
Ali Vasheghani-Farahani
MTMaryam Tahmasbi
Maryam Tahmasbi
HAHossein Asheri
Hossein Asheri
HAHaleh Ashraf
Haleh Ashraf
SNSaharnaz Nedjat
Saharnaz Nedjat
RKRamin Kordi
Ramin Kordi
To translate long form, interview-administered International Physical Activity Questionnaire (IPAQ) from English to Persian and evaluate its validity, reliability and reproducibility.A forward-backward translation procedure was followed to develop the Persian version of the IPAQ. A total of 218 respondents (53.7% women, aged 2276 yr) completed the Persian version in Tehran, Iran. To examine the testretest reliability, 48 healthy volunteers completed the IPAQ twice during a 7-day period.. The PA indicators derived from the IPAQ were assessed for reliability and were compared with aerobic fitness and body mass index (BMI) for construct validity.In general, the questionnaire was received well and all domains met the minimum reliability standards (intra-class correlation [ICC]>0.7), except for Leisure-time physical activity (PA). Aerobic fitness showed a weak positive correlation with all of the PA results derived from the IPAQ. A significant correlation was observed between the IPAQ data for total PA and both aerobic fitness (r=0.33, P<0.001) and BMI (r=0.26, P<0.001). Performing a known group comparison analysis, the results indicated that the questionnaire was discriminated well between the subgroups of the study samples expected to be different in their physical activity.The Persian version of the long form, interview-administered IPAQ had an acceptable reliability and validity for assessing total PA in our Iranian sample of individuals. It may be a useful instrument for generating internationally comparable data on PA.

3 November 2009 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SZSophia Zoungas
Sophia Zoungas
TNToshiharu Ninomiya
Toshiharu Ninomiya
Rachel HuxleyRachel Huxley
Rachel Huxley
ACAlan Cass
Alan Cass
MJMeg Jardine
Meg Jardine
VPVlado Perkovic
Vlado Perkovic
Intravenous sodium bicarbonate has been proposed to reduce the risk for contrast-induced nephropathy (CIN). To determine the effect of sodium bicarbonate on the risk for CIN. MEDLINE, PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials from 1950 to December 2008; conference proceedings; and ClinicalTrials.gov, without language restriction. Randomized, controlled trials of intravenous sodium bicarbonate that prespecified the outcome of CIN as a 25% increase in baseline serum creatinine level or an absolute increase of 44 μmol/L (0.5 mg/dL) after radiocontrast administration. Using standardized protocols, 2 reviewers serially abstracted data for each study. 23 published and unpublished trials with information on 3563 patients and 396 CIN events were included. The pooled relative risk was 0.62 (95% CI, 0.45 to 0.86), with evidence of significant heterogeneity across studies (I2 = 49.1%; P = 0.004). Some heterogeneity was due to the difference in the estimates between published and unpublished studies: relative risk, 0.43 (CI, 0.25 to 0.75) versus 0.78 (CI, 0.52 to 1.17), respectively. Meta-regression showed that small, poor-quality studies that assessed outcomes soon after radiocontrast administration were more likely to suggest benefit (P < 0.05 for all). No clear effects of treatment on the risk for dialysis, heart failure, and total mortality were identified. Power to assess clinical end points was limited. The effectiveness of sodium bicarbonate treatment to prevent CIN in high-risk patients remains uncertain. Earlier reports probably overestimated the magnitude of any benefit, whereas larger, more recent trials have had neutral results. Large multicenter trials are required to clarify whether sodium bicarbonate has value for prevention of CIN before routine use can be recommended. None.

1 October 2009 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
AVAli Vasheghani-Farahani
Ali Vasheghani-Farahani
GSGelareh Sadigh
Gelareh Sadigh
SKSeyed Ebrahim Kassaian
Seyed Ebrahim Kassaian
SKSeyed Mohammad Reza Khatami
Seyed Mohammad Reza Khatami
AFAkbar Fotouhi
Akbar Fotouhi
SDSirous Darabian
Sirous Darabian

15 October 2011 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
AVAli Vasheghani-Farahani
Ali Vasheghani-Farahani
MSMohammad Ali Sahraian
Mohammad Ali Sahraian
LDLeila Darabi
Leila Darabi
AAAida Aghsaie
Aida Aghsaie
AMAlireza Minagar
Alireza Minagar

29 April 2023 in Clinical Autonomic Research
Verified
Journal Article
Closed access
PDF file
DSDanesh Soltani
Danesh Soltani
BABayan Azizi
Bayan Azizi
SSSepehr Sima
Sepehr Sima
KTKiarash Tavakoli
Kiarash Tavakoli
NMNegin Sadat Hosseini Mohammadi
Negin Sadat Hosseini Mohammadi
AVAli Vasheghani-Farahani
Ali Vasheghani-Farahani

30 August 2022 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
SKShaghayegh Khanmohammadi
Shaghayegh Khanmohammadi
HTHamed Tavolinejad
Hamed Tavolinejad
AAArya Aminorroaya
Arya Aminorroaya
YRYasaman Rezaie
Yasaman Rezaie
HAHaleh Ashraf
Haleh Ashraf
AVAli Vasheghani-Farahani
Ali Vasheghani-Farahani